A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
Author:
Publisher
Elsevier BV
Reference32 articles.
1. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007
2. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis;Zhu;Transl Lung Cancer Res,2015
3. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer;Kazandjian;Oncologist,2016
4. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials;Drilon;Lancet Oncol,2020
5. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins;Neel;Cancer Res,2019
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23
2. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;Nature Communications;2024-06-14
3. Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors;Cancer Medicine;2024-04
4. Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress;Cold Spring Harbor Perspectives in Medicine;2024-03-11
5. Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer;JCO Oncology Practice;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3